ReviewEuropean heart journal2026
T cells in acute and chronic myocarditis: from diagnosis to treatment.
Review in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07481136 (A Phase I PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Acute Myocarditis), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Acute Myocarditis
Who cites it
3 citing papers in PubMed.
- The Cardio-Onco-Immune Axis: immunopathological mechanisms in the cardiac microenvironment of checkpoint inhibitor-induced myocarditis.Acta pharmacologica Sinica · 2026Review
- Myocardial Immune Niches in Homeostasis and Inflammation.Immunological reviews · 2026Review
- Toll-like receptors in infectious myocarditis: pathogen-specific recognition, spatiotemporal dynamic regulation and clinical translation.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Myocarditis refers to infiltration of immune cells into the heart causing inflammation and cardiomyocyte damage. Clinically, myocarditis can be acute or chronic. While the clinical and pathological syndrome of myocarditis has been recognized for more than a century, newer aetiologies for myocarditis have emerged in the past decade. These include myocarditis associated with immune checkpoint inhibitors, or myocarditis linked to chronic inflammatory and genetic diseases. With the emergence of immune checkpoint inhibitor-associated myocarditis, the breakdown of T cell tolerance has been recognized as a key mechanism in disease development. The main focus of this review is to integrate existing models of myocarditis into an overarching immunological concept. Through the lens of loss of immune tolerance, this review focuses on diagnosis and treatment of myocarditis. Starting from acute myocarditis as paradigmatic inflammatory condition of the heart, this review outlines future research frontiers for myocardial inflammatory disease including new approaches to diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.